BEIJING, Dec. 2 SVA-Vaccine-Suspended
BEIJING, Dec. 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Alternext
US: SVA), a leading provider of vaccines in China, announced today that, the
Health Services Bureau of Fengtai District in the City of Beijing suspended
the use of 83 doses of inactivated hepatitis A vaccine Healive(R), following a
report of the death of a minor in the Fengtai District on November 27, 2008,
which coincided with the administration of the vaccine two days prior.
The suspended vaccine was part of lot 2008052105 that passed the routine
government inspection in July 2008. To date, 19,850 doses vaccines from the
lot have been distributed. According to data released by the Center for
Adverse Drug Reaction Monitoring of Beijing, there is no other reported
adverse reaction to the lot to date. Sinovac has not received, and is not
aware of, similar notice of suspension from any other district in Beijing
where the lot has been distributed or any other part of China where other lots
of the Healive(R) vaccine have been distributed. On November 29, 2008, the
Beijing Drug Administration and Drug Administration of Haidian District of
City of Beijing conducted a joint administrative investigation that included
an inspection of the company's manufacturing site and review of its
manufacturing, inspection and sales processes, and concluded in a written
report that no abnormality was found.
Sinovac has full confidence in the quality of its products. It will
continue to cooperate with government agencies in their investigation of the
incident and will provide an update once the investigation is completed.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacture and commercialization of
vaccines that protect against human infectious diseases. Sinovac's
commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined
hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac is
currently developing Universal Pandemic Influenza vaccine and Japanese
encephalitis vaccine. Additional information about Sinovac is available on
its website, http://www.sinovac.com . To be added to our distribution list,
please email: info@sinovac.com.
For more information, please contact:
Helen G. Yang
Sinovac Biotech Ltd.
Tel: +86-10-8289-0088 x871
Fax: +86-10-6296-6910
Email: info@sinovac.com
Investors/Media:
Stephanie Carrington / Janine McCargo
The Ruth Group
Tel: +1-646-536-7017/7033
Email: scarrington@theruthgroup.com / jmccargo@theruthgroup.com
SOURCE Sinovac Biotech Ltd.
